Rational Design of Combinations for the Treatment of Advanced Cancer
@article{Komiya2016RationalDO, title={Rational Design of Combinations for the Treatment of Advanced Cancer}, author={T. Komiya}, journal={Cancer clinical trials}, year={2016}, volume={1}, pages={122} }
Despite our enormous effort and progress in medicine, cancer remains a top health issue worldwide. According to recent statistics, more than eight million people annually succumb to the disease in the world [1]. It is clear that we must work much harder in order to eliminate this disease in the next several decades. We have a hope, however, that can encourage us to do so and move forward: cancer immunotherapy. Systemic immunotherapy for the treatment of cancer has been investigated for many… CONTINUE READING
Topics from this paper
One Citation
References
SHOWING 1-10 OF 21 REFERENCES
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Biology, Medicine
- Science
- 2015
- 3,996
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
- Medicine
- The New England journal of medicine
- 2015
- 4,956
- PDF
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
- Medicine
- The New England journal of medicine
- 2015
- 5,110
- PDF
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Medicine
- The Lancet
- 2016
- 3,169
- PDF
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
- Medicine
- The New England journal of medicine
- 2010
- 4,112
- PDF
Nivolumab in previously untreated melanoma without BRAF mutation.
- Medicine
- The New England journal of medicine
- 2015
- 3,536
- PDF
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2004
- 1,731
- PDF
PD-1 blockade in tumors with mismatch repair deficiency.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2015
- 2,143
- PDF
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2004
- 1,712
- PDF